International Agency for Research on Cancer, Lyon, France.
Drug Discov Today. 2013 Sep;18(17-18):894-905. doi: 10.1016/j.drudis.2013.05.005. Epub 2013 May 17.
Parthenolide (PTL), a sesquiterpene lactone (SL) originally purified from the shoots of feverfew (Tanacetum parthenium), has shown potent anticancer and anti-inflammatory activities. It is currently being tested in cancer clinical trials. Structure-activity relationship (SAR) studies of parthenolide revealed key chemical properties required for biological activities and epigenetic mechanisms, and led to the derivatization of an orally bioavailable analog, dimethylamino-parthenolide (DMAPT). Parthenolide is the first small molecule found to be selective against cancer stem cells (CSC), which it achieves by targeting specific signaling pathways and killing cancer from its roots. In this review, we highlight the exciting journey of parthenolide, from plant shoots to cancer roots.
小白菊内酯(PTL)是一种倍半萜内酯(SL),最初从银胶菊(Tanacetum parthenium)的芽中纯化出来,具有很强的抗癌和抗炎活性。它目前正在癌症临床试验中进行测试。小白菊内酯的构效关系(SAR)研究揭示了生物活性和表观遗传机制所需的关键化学性质,并导致了可口服生物利用的类似物二甲氨基小白菊内酯(DMAPT)的衍生化。小白菊内酯是第一种被发现对癌症干细胞(CSC)具有选择性的小分子,它通过靶向特定的信号通路并从根源上杀死癌细胞来实现这一目标。在这篇综述中,我们强调了小白菊内酯从植物芽到癌症根源的令人兴奋的历程。